A predictive nomogram for short-term outcomes of myasthenia gravis patients treated with low-dose rituximab

被引:0
作者
Zhou, Yufan [1 ,2 ,3 ]
Guo, Rongjing [4 ]
Xia, Xingyu [1 ,2 ,3 ]
Jing, Sisi [5 ]
Lu, Jun [1 ,2 ,3 ]
Ruan, Zhe [4 ]
Luo, Sushan [1 ,2 ,3 ]
Huan, Xiao [1 ,2 ,3 ]
Zhao, Chongbo [1 ,2 ,3 ]
Chang, Ting [4 ]
Xi, Jianying [1 ,2 ,3 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai, Peoples R China
[2] Fudan Univ, Huashan Hosp, Huashan Rare Dis Ctr, Shanghai, Peoples R China
[3] Natl Ctr Neurol Dis, Shanghai, Peoples R China
[4] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian, Peoples R China
[5] Chongqing Med Univ, Banan Hosp, Dept Neurol, Chongqing, Peoples R China
关键词
myasthenia gravis; nomogram; predictor; prognosis; rituximab; RECEPTOR POLYMORPHISMS; SAFETY; ASSOCIATION; CELLS; GENE;
D O I
10.1111/cns.14761
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
BackgroundThis study aims to establish and validate a predictive nomogram for the short-term clinical outcomes of myasthenia gravis (MG) patients treated with low-dose rituximab.MethodsWe retrospectively reviewed 108 patients who received rituximab of 600 mg every 6 months in Huashan Hospital and Tangdu Hospital. Of them, 76 patients from Huashan Hospital were included in the derivation cohort to develop the predictive nomogram, which was externally validated using 32 patients from Tangdu Hospital. The clinical response is defined as a >= 3 points decrease in QMG score within 6 months. Both clinical and genetic characteristics were included to screen predictors via multivariate logistic regression. Discrimination and calibration were measured by the area under the receiver operating characteristic curve (AUC-ROC) and Hosmer-Lemeshow test, respectively.ResultsDisease duration (OR = 0.987, p = 0.032), positive anti-muscle-specific tyrosine kinase antibodies (OR = 19.8, p = 0.007), and genotypes in FCGR2A rs1801274 (AG: OR = 0.131, p = 0.024;GG:OR = 0.037, p = 0.010) were independently associated with clinical response of post-rituximab patients. The nomogram identified MG patients with clinical response with an AUC-ROC (95% CI) of 0.875 (0.798-0.952) in the derivation cohort and 0.741(0.501-0.982) in the validation cohort. Hosmer-Lemeshow test showed a good calibration (derivation: Chi-square = 3.181, p = 0.923; validation: Chi-square = 8.098, p = 0.424).ConclusionsThe nomogram achieved an optimal prediction of short-term outcomes in patients treated with low-dose rituximab. Our study developed and validated the clinical response prediction nomogram for myasthenia gravis patients treated with low-dose rituximab. The nomogram can effectively identify patients with clinical response, help make treatment-related decisions, alleviate the financial burden on patients, and rationalize the allocation of healthcare resources.image
引用
收藏
页数:9
相关论文
共 44 条
[1]   Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis [J].
Alberici, Federico ;
Smith, Rona M. ;
Fonseca, Mariana ;
Willcocks, Lisa C. ;
Jones, Rachel B. ;
Holle, Julia U. ;
Wieczorek, Stefan ;
Neumann, Thomas ;
Martorana, Davide ;
Gregorini, Gina ;
Sinico, Renato A. ;
Bruchfeld, Annette ;
Gunnarsson, Iva ;
Ohlsson, Sophie ;
Baslund, Bo ;
Tesar, Vladimir ;
Hruskova, Zdenka ;
Cid, Maria C. ;
Vaglio, Augusto ;
Lyons, Paul A. ;
Smith, Kenneth G. C. ;
Jayne, David R. W. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (05) :1684-+
[2]   Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: a meta-analysis [J].
Antonatos, Charalabos ;
Stavrou, Eleana F. ;
Evangelou, Evangelos ;
Vasilopoulos, Yiannis .
PHARMACOGENOMICS, 2021, 22 (07) :435-445
[3]   Muscle satellite cells are functionally impaired in myasthenia gravis: consequences on muscle regeneration [J].
Attia, Mohamed ;
Maurer, Marie ;
Robinet, Marieke ;
Le Grand, Fabien ;
Fadel, Elie ;
Le Panse, Rozen ;
Butler-Browne, Gillian ;
Berrih-Aknin, Sonia .
ACTA NEUROPATHOLOGICA, 2017, 134 (06) :869-888
[4]   Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis [J].
Bastakoti, Sanjiv ;
Kunwar, Saru ;
Poudel, Sujan ;
Quinonez, Jonathan ;
Bista, Seema ;
Singh, Navpreet ;
Jha, Vivek ;
Ruxmohan, Samir ;
Paesani, Sylvia ;
Cueva, Wilson ;
Michel, Jack .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
[5]   Myasthenia gravis: a clinical-immunological update [J].
Binks, Sophie ;
Vincent, Angela ;
Palace, Jacqueline .
JOURNAL OF NEUROLOGY, 2016, 263 (04) :826-834
[6]   IgG Fc receptor polymorphisms in human disease: Implications for intravenous immunoglobulin therapy [J].
Binstadt, BA ;
Geha, RS ;
Bonilla, FA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (04) :697-703
[7]   Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis [J].
Brauner, Susanna ;
Eriksson-Dufva, Ann ;
Hietala, Max Albert ;
Frisell, Thomas ;
Press, Rayomand ;
Piehl, Fredrik .
JAMA NEUROLOGY, 2020, 77 (08) :974-981
[8]   Structural analysis of Fc/FcR complexes: a blueprint for antibody design [J].
Caaveiro, Jose M. M. ;
Kiyoshi, Masato ;
Tsumoto, Kouhei .
IMMUNOLOGICAL REVIEWS, 2015, 268 (01) :201-221
[9]   Influence of variants of Fcγ receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to antitumour necrosis factor α therapy in rheumatoid arthritis [J].
Canete, J. D. ;
Suarez, B. ;
Hernandez, M. V. ;
Sanmarti, R. ;
Rego, I. ;
Celis, R. ;
Moll, C. ;
Pinto, J. A. ;
Blanco, F. J. ;
Lozano, F. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (10) :1547-1552
[10]   Genetic polymorphism studies in periodontitis and Fcγ receptors [J].
Chai, L. ;
Song, Y. -Q. ;
Leung, W. K. .
JOURNAL OF PERIODONTAL RESEARCH, 2012, 47 (03) :273-285